Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: LON:HIK
- CUSIP: N/A
- Web: www.hikma.com/
Capitalization:- Market Cap: £3.65 billion
- Outstanding Shares: 240,959,000
Average Prices:- 50 Day Moving Avg: GBX 1,734.89
- 200 Day Moving Avg: GBX 1,885.94
- 52 Week Range: GBX 1,514 - GBX 2,703
P/E:- Trailing P/E Ratio: 22.46
- P/E Growth: 0.84
Sales & Book Value:- Annual Revenue: £1.95 billion
- Price / Sales: 1.87
- Book Value: GBX 9.94 per share
- Price / Book: 1.53
Dividend:
Profitability:- EBIDTA: £446 million
- Net Margins: 9.27%
- Return on Equity: 8.09%
- Return on Assets: 4.45%
Misc:- Average Volume: 815,900 shs.
Frequently Asked Questions for Hikma Pharmaceuticals Plc (LON:HIK)
What is Hikma Pharmaceuticals Plc's stock symbol?
Hikma Pharmaceuticals Plc trades on the London Stock Exchange (LON) under the ticker symbol "HIK."
How often does Hikma Pharmaceuticals Plc pay dividends? What is the dividend yield for Hikma Pharmaceuticals Plc?
Hikma Pharmaceuticals Plc declared a dividend on Wednesday, March 15th. Investors of record on Thursday, April 6th will be given a dividend of GBX 0.22 per share on Thursday, May 25th. This represents a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, April 6th. This is an increase from Hikma Pharmaceuticals Plc's previous dividend of $0.21. The official announcement can be accessed at this link. View Hikma Pharmaceuticals Plc's Dividend History.
When will Hikma Pharmaceuticals Plc make its next earnings announcement?
Where is Hikma Pharmaceuticals Plc's stock going? Where will Hikma Pharmaceuticals Plc's stock price be in 2017?
10 analysts have issued 1-year target prices for Hikma Pharmaceuticals Plc's shares. Their predictions range from GBX 1,410 to GBX 2,900. On average, they anticipate Hikma Pharmaceuticals Plc's share price to reach GBX 2,138.10 in the next year. View Analyst Ratings for Hikma Pharmaceuticals Plc.
Who are some of Hikma Pharmaceuticals Plc's key competitors?
Some companies that are related to Hikma Pharmaceuticals Plc include Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT), Akorn (AKRX), Opko Health (OPK), BTG plc (BTG), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Horizon Pharma PLC (HZNP), Pacira Pharmaceuticals (PCRX), Amicus Therapeutics (FOLD), Innoviva (INVA), Corcept Therapeutics Incorporated (CORT), Impax Laboratories (IPXL), Amphastar Pharmaceuticals (AMPH) and Lannett Co (LCI).
Who are Hikma Pharmaceuticals Plc's key executives?
Hikma Pharmaceuticals Plc's management team includes the folowing people:
- Said Darwazah, Chairman of the Board, Chief Executive
- Mazen Samih Talib Darwazah, Executive Vice Chairman of the Board, President and Chief Executive Officer of MENA and Emerging Markets
- Khalid Nabilsi, Chief Financial Officer
- Brian Hoffman, President, West-Ward Pharmaceuticals
- Michael Raya, Chief Executive Officer, West-Ward Pharmaceuticals
- Majda Labadi, Corporate Vice President - Human Resources and Head of Operations, MENA
- Riad Mishlawi, EU Vice President and Global Head - Injectables
- Susan Ringdal, Vice President - Corporate Strategy and Investor Relations
- Hussein Arkhagha, General Counsel
- Bassam Wael Rushdi Kanaan, Chief Strategy and Corporate Development Officer
How do I buy Hikma Pharmaceuticals Plc stock?
Shares of Hikma Pharmaceuticals Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Hikma Pharmaceuticals Plc's stock price today?
One share of Hikma Pharmaceuticals Plc stock can currently be purchased for approximately GBX 1,516.
MarketBeat Community Rating for Hikma Pharmaceuticals Plc (LON HIK)MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Hikma Pharmaceuticals Plc (LON:HIK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 3 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.30) |
| Consensus Price Target: | GBX 2,138.10 |
Analysts' Ratings History for Hikma Pharmaceuticals Plc (LON:HIK)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 6/27/2017 | HSBC Holdings plc | Lower Price Target | Reduce | GBX 1,700 -> GBX 1,410 |  |
| 6/27/2017 | J P Morgan Chase & Co | Reiterated Rating | Neutral | GBX 1,500 | |
| 6/2/2017 | Jefferies Group LLC | Reiterated Rating | Underperform | GBX 1,450 | |
| 5/19/2017 | Numis Securities Ltd | Reiterated Rating | Add | GBX 2,000 | |
| 4/4/2017 | Stifel Nicolaus | Reiterated Rating | Buy | GBX 2,550 | |
| 3/30/2017 | Peel Hunt | Reiterated Rating | Buy | | |
| 11/30/2016 | AlphaValue | Reiterated Rating | Buy | GBX 2,431 | |
| 11/16/2016 | Citigroup Inc. | Reiterated Rating | Neutral | | |
| 11/15/2016 | Morgan Stanley | Upgrade | Equal Weight -> Overweight | GBX 2,500 -> GBX 2,200 | |
| 9/9/2016 | Barclays PLC | Reiterated Rating | Overweight | GBX 2,900 | |
| 3/16/2016 | Panmure Gordon | Upgrade | Buy | GBX 2,120 | |
| 9/15/2015 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Buy | | |
| 9/2/2015 | Shore Capital | Upgrade | Buy | | |
(Data available from 6/28/2015 forward)
Earnings History for Hikma Pharmaceuticals Plc (LON:HIK)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Hikma Pharmaceuticals Plc (LON:HIK)Current Year EPS Consensus Estimate: $1.08 EPS
Dividend History by Quarter for Hikma Pharmaceuticals Plc (LON HIK)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 3/15/2017 | | €0.22 | 0.78% | 4/6/2017 | 4/6/2017 | 5/25/2017 |
| 3/11/2015 | | €0.21 | 0.64% | 4/16/2015 | 4/16/2015 | 5/21/2015 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Hikma Pharmaceuticals Plc (LON:HIK)Insider Trades by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/19/2016 | Ali Al-Husry | Insider | Buy | 50,000 | GBX 1,790 | £895,000 | |
| 12/16/2016 | Mazen Darwazah | Insider | Buy | 90,730 | GBX 1,849 | £1,677,597.70 | |
| 12/12/2016 | Ali Al-Husry | Insider | Buy | 50,000 | GBX 1,707 | £853,500 | |
| 12/9/2016 | Ali Al-Husry | Insider | Buy | 50,000 | GBX 1,723 | £861,500 | |
| 12/6/2016 | Ali Al-Husry | Insider | Buy | 100,000 | GBX 1,682 | £1,682,000 | |
| 12/5/2016 | Ali Al-Husry | Insider | Buy | 50,000 | GBX 1,674 | £837,000 | |
| 12/2/2016 | Mazen Darwazah | Insider | Buy | 50,000 | GBX 1,662 | £831,000 | |
| 12/1/2016 | Mazen Darwazah | Insider | Buy | 50,000 | GBX 1,674 | £837,000 | |
| 11/30/2016 | Said Darwazah | Insider | Buy | 50,000 | GBX 1,662 | £831,000 | |
| 9/28/2016 | Said Darwazah | Insider | Buy | 10,000 | GBX 2,085 | £208,500 | |
| 9/27/2016 | Ali Al-Husry | Insider | Buy | 50,000 | GBX 2,094 | £1,047,000 | |
| 9/26/2016 | Said Darwazah | Insider | Buy | 50,000 | GBX 2,078 | £1,039,000 | |
| 9/23/2016 | Ali Al-Husry | Insider | Buy | 50,000 | GBX 2,099 | £1,049,500 | |
| 9/21/2016 | Ali Al-Husry | Insider | Buy | 50,000 | GBX 2,138 | £1,069,000 | |
| 9/16/2016 | Al-Husry,Ali | Insider | Buy | 50,000 | GBX 2,119 | £1,059,500 | |
| 9/15/2016 | Darwazah,Said | Insider | Buy | 70,251 | GBX 2,122 | £1,490,726.22 | |
| 9/8/2016 | Darwazah,Mazen | Insider | Buy | 150,000 | GBX 2,162 | £3,243,000 | |
| 9/6/2016 | Darwazah,Mazen | Insider | Buy | 155,991 | GBX 2,194 | £3,422,442.54 | |
| 8/31/2016 | Al-Husry,Ali | Insider | Buy | 140,000 | GBX 2,150 | £3,010,000 | |
| 8/26/2016 | Darwazah,Said | Insider | Buy | 200,000 | GBX 2,160 | £4,320,000 | |
| 6/24/2016 | Darwazah,Mazen | Insider | Buy | 150,000 | GBX 2,200 | £3,300,000 | |
| 6/17/2016 | Al-Husry,Ali | Insider | Buy | 70,000 | GBX 22 | £15,400 | |
| 5/9/2016 | Darwazah,Said | Insider | Buy | 17,440 | GBX 2,228 | £388,563.20 | |
| 4/26/2016 | Darwazah,Said | Insider | Buy | 10,000 | GBX 2,260 | £226,000 | |
| 4/25/2016 | Darwazah,Said | Insider | Buy | 10,000 | GBX 2,324 | £232,400 | |
| 4/22/2016 | Darwazah,Said | Insider | Buy | 30,000 | GBX 2,325 | £697,500 | |
| 4/20/2016 | Darwazah,Said | Insider | Buy | 30,000 | GBX 2,271 | £681,300 | |
| 4/19/2016 | Darwazah,Said | Insider | Buy | 30,000 | GBX 2,266 | £679,800 | |
| 4/11/2016 | J. Castellani,John | Insider | Buy | 2,500 | GBX 2,103 | £52,575 | |
| 4/7/2016 | Darwazah,Mazen | Insider | Buy | 60,000 | GBX 2,118 | £1,270,800 | |
| 4/5/2016 | Darwazah,Said | Insider | Buy | 30,000 | GBX 2,055 | £616,500 | |
| 3/31/2016 | Darwazah,Said | Insider | Buy | 30,000 | GBX 1,972 | £591,600 | |
| 3/24/2016 | Butler,Pat | Insider | Buy | 2,500 | GBX 1,920 | £48,000 | |
| 3/21/2016 | Pickering ,Robert | Insider | Buy | 2,500 | GBX 1,856 | £46,400 | |
| 8/27/2015 | Kirby,Pamela | Insider | Buy | 3,317 | GBX 2,264 | £75,096.88 | |
(Data available from 1/1/2013 forward)
Headline Trends for Hikma Pharmaceuticals Plc (LON:HIK)
Latest Headlines for Hikma Pharmaceuticals Plc (LON:HIK)
| Source: |
|
Hikma Pharmaceuticals Plc (HIK) Chart for Wednesday, June, 28, 2017
